Web8 apr. 2024 · MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. About the company Rewards Revenue is forecast to grow 23.9% per year Risk Analysis Earnings are forecast to decline by an average of 4.9% per year for the next 3 years Web8 mrt. 2024 · MaxCyte’s Scientific Advisory Board will provide guidance to shape the technical direction of the company’s innovation initiatives focused on the discovery, …
Did you know?
Web7 sep. 2024 · US IR Adviser Gilmartin Group David Deuchler, CFA +1 415-937-5400 [email protected]: Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden +44 (0)20 7886 2500: UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh +44 (0)203 … Web12 okt. 2024 · ROCKVILLE, Md., Oct. 12, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company …
Web12 apr. 2024 · According to analysts' consensus price target of $10.50, MaxCyte has a forecasted upside of 108.3% from its current price of $5.04. Amount of Analyst Coverage MaxCyte has only been the subject of 1 research reports in the past 90 days. See Top Rated MarketRank™ Stocks Here About MaxCyte (NASDAQ:MXCT) Stock Web12 apr. 2024 · ROCKVILLE, Md., April 12, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, ... US IR Adviser Gilmartin Group David Deuchler, CFA +1 415-937-5400 [email protected]. Nominated Adviser and Joint …
Web8 mrt. 2024 · ROCKVILLE, Md., March 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, … Web22 mrt. 2024 · MaxCyte Corporate Presentation NASDAQ: MXCT • LSE: MXCT March 22, 2024 are trademarks of MaxCyte, Inc. in the U.S.A. [email protected] …
WebGet the latest MaxCyte Inc (MXCT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Web15 mrt. 2024 · ROCKVILLE, Md., March 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell … southlingsWeb11 apr. 2024 · MaxCyte, Inc. 5,723 followers 1mo With the launch of our brand refresh, MaxCyte is entering a new era! We recognize that you need more than just technology to … teaching kitten to walk on leashWebMaxCyte is a leading provider of cell-engineering platform technologies that are advancing innovative cell-based research, development and potential commercialization of … News and Events - Investor Relations MaxCyte Inc Email Alerts Company Information Advisers Contact IR This area of the web site … The Investor Relations website contains information about MaxCyte Inc's … Corporate Governance & Internal Controls. The Directors are committed to … MaxCyte Minutes Newsletter; Events; Investors; Ask the ExPERT; Menu. … The Investor Relations website contains information about MaxCyte Inc's … Documents and Presentations - Investor Relations MaxCyte Inc NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have … southline transmission projectWeb6 mrt. 2024 · ROCKVILLE, Md. , March 6, 2024 /PRNewswire/ -- MaxCyte, Inc., (NASDAQ: MXCT) (LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the... southline little leagueWeb1 dag geleden · MXCT 4.14%. 54. See MXCT Report. MaxCyte to Report First Quarter 2024 Financial Results on May 10, 2024. ROCKVILLE, Md., April 12, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, … southline transmissionWeb13 sep. 2024 · MaxCyte Contacts: US IR Adviser Gilmartin Group +1 415-937-5400: David Deuchler, CFA: [email protected] Nominated Adviser and Joint Corporate Broker teaching kjvWeb1 dag geleden · MaxCyte to Report First Quarter 2024 Financial Results on May 10, 2024. ROCKVILLE, Md., April 12, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering ... teaching knife skills